Literature DB >> 2849668

Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia.

B Gotti1, D Duverger, J Bertin, C Carter, R Dupont, J Frost, B Gaudilliere, E T MacKenzie, J Rousseau, B Scatton.   

Abstract

Recent studies have strongly implicated the excitatory neurotransmitter glutamate in the cascade of pathological mechanisms that cause neuronal loss after certain types of brain ischemia. The neurotoxic effects of glutamate are mediated, at least in global ischemia, via NMDA receptors. In the present study we have examined the effects of compounds that possess NMDA receptor antagonist properties (ifenprodil, SL 82.0715 [(+/-)-alpha-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]- 1-piperidineethanol] and 1-[1-(2-thienyl)cyclohexyl]piperidine) on the histological consequences of focal, as opposed to global, cerebral ischemia in both the rat and the cat. Ifenprodil (0.3-3 mg/kg i.v.) administered as a perfusion over 3 hr after occlusion of the feline middle cerebral artery reduced the volume of infarcted tissue (measured 4 days after occlusion) in a dose-related manner. At the highest dose a 42% reduction of infarcted volume was noted, essentially in cortical tissue. In an identical protocol, a derivative of ifenprodil, SL 82.0715, reduced the volume of infarction in a manner comparable to that described for ifenprodil. As SL 82.0715 possesses better p.o. bioavailability, this compound was also evaluated in the rat, again after middle cerebral artery occlusion. First administered 30 min after the induction of ischemia, SL 82.0715 (1 and 10 mg/kg p.o.) reduced infarction volume by 34 and 48%, respectively. The quantitative histology was performed 2 days after middle cerebral artery occlusion. The noncompetitive receptor antagonist, 1-[1-(2-thienyl)cyclohexyl]piperidine, administered (1 mg/kg i.p.) before the induction of focal ischemia, similarly and significantly decreased the final volume of infarction. As both ifenprodil and SL 82.0715 are noncompetitive antagonists of the NMDA receptor, two conclusions may be drawn from the present investigation. First, NMDA antagonism by ifenprodil and its derivative is an effective approach for tissue sparing in animal models of stroke and brain infarction. Second, these pharmacological observations provide evidence for the involvement of excitatory amino-acid induced-neurotoxicity in the evolution and consequences of focal cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849668

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.

Authors:  V Pedersen; W J Schmidt
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  Autoradiographic assessment of the effects of N-methyl-D-aspartate (NMDA) receptor antagonists in vivo.

Authors:  J McCulloch; L L Iversen
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

4.  Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice.

Authors:  D J Sanger; D Joly
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators.

Authors:  Pieter B Burger; Hongjie Yuan; Erkan Karakas; Matthew Geballe; Hiro Furukawa; Dennis C Liotta; James P Snyder; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

Review 6.  Neuroprotection for ischemic stroke: two decades of success and failure.

Authors:  Yu Dennis Cheng; Lama Al-Khoury; Justin A Zivin
Journal:  NeuroRx       Date:  2004-01

Review 7.  A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/glycine/ion channel receptor macrocomplex.

Authors:  P L Wood; T S Rao; S Iyengar; T Lanthorn; J Monahan; A Cordi; E Sun; M Vazquez; N Gray; P Contreras
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

Review 8.  Ion channels as drug targets in central nervous system disorders.

Authors:  A M Waszkielewicz; A Gunia; N Szkaradek; K Słoczyńska; S Krupińska; H Marona
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

9.  Proceedings of the British Pharmacological Society Meeting. Sheffield, 18-20th April 1990.

Authors: 
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

10.  An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones.

Authors:  J N Kew; J A Kemp
Journal:  J Physiol       Date:  1998-10-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.